COR — Cencora, Inc.

Cencora Inc. Q2 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Adjusted Diluted EPS: $4.75, up 7.5% year-over-year.
• Consolidated Revenue: $78.4 billion, a 4% increase driven by both U.S. and International Healthcare Solutions segments.
• Gross Profit: $3.4 billion, up 16%, with a gross profit margin of 4.31%, an increase of 45 basis points.
• Operating Income: $1.3 billion, a 6% increase compared to the prior year.
• Cash Position: $2.2 billion with $1.1 billion in free cash flow generated in the quarter.
• Interest Expense: $140 million, up $36 million year-over-year.
• Full Year Adjusted Free Cash Flow Guidance: Approximately $3 billion remains unchanged.

2. Strategic Updates and Business Highlights

• Digital Transformation: Continued investment in digital infrastructure and AI-supported tools to enhance customer support and operational efficiency.
• Specialty Pharmaceuticals: Strengthening position through management services organizations (MSOs) and global specialty logistics, with new contracts in cell and gene therapies.
• Portfolio Optimization: Merged MWI Animal Health with Covetrus and divested U.S. hub consulting services to focus on pharmaceutical-centric strategy.
• Resumption of Share Repurchases: Announced opportunistic share repurchases of $1 billion by year-end.

3. Forward Guidance and Outlook

• Adjusted EPS Guidance: Raised to $17.65 - $17.90, up from $17.45 - $17.75.
• Revenue Growth Guidance: Adjusted to 4% - 6%, down from 7% - 9%, primarily due to lower expectations for U.S. Healthcare Solutions and GLP-1 growth.
• Operating Income Growth Guidance: Increased to 12% - 14%, up from 11.5% - 13.5%.
• International Revenue Growth: Expected to be 8% - 10% on an as-reported basis.

4. Bad News, Challenges, or Points of Concern

• Revenue Headwinds: Experienced a $2 billion revenue headwind from manufacturer list price reductions and a loss of an oncology customer, impacting growth expectations.
• Impact of Brand Conversions: Faster-than-expected brand conversions at a large mail order pharmacy customer contributed to reduced revenue growth.
• Weather Effects: Inclement weather led to lower patient appointment volumes, impacting operating income by an estimated $10 million.
• COVID-19 Vaccine Contribution Decline: Operating income from COVID-19 vaccines decreased, contributing to headwinds.

5. Notable Q&A Insights

• Long-term Growth Concerns: Analysts raised questions about the impact of increasing generics and biosimilars on profit pools, particularly in specialty pharmaceuticals.
• Operating Profit Dynamics: Management emphasized confidence in maintaining dollar profit margins despite pricing pressures, attributing this to the quality and efficiency of services provided.
• Market Behavior: Management noted that while some revenue pressures exist, they expect to see a rebound in patient volumes and specialty product sales in the latter half of the fiscal year.
• MSO Integration: Positive feedback on the integration of OneOncology and RCA, with expectations of enhanced collaboration and value delivery to practices.

Overall, Cencora reported solid financial performance in Q2 2026, with strategic initiatives aimed at enhancing its position in the pharmaceutical supply chain, despite facing some revenue headwinds and challenges in the U.S. Healthcare Solutions segment. The company remains optimistic about its growth trajectory and operational efficiencies moving forward.